Parkinson's affects more than 1 million people in the US. Only 10 to 20% of people with Parkinson's experience symptoms ...

The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.

A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that ...

Managing patients with Parkinson's disease should be viewed as part of a hospital CMO's responsibility for patient safety and ...

Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study.

Growing older is the greatest risk factor for acquiring Parkinson’s disease and many people live with symptoms for several years before being diagnosed. Often people in early stages of Parkinson’s ...

What's normal? Temporary shaking can occur after physical exertion, stress, or as a side effect of medication. Difficulty ...

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to ...

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...

Parkinson’s disease is a challenging condition that affects millions of people around the world. It is known for causing ...

The new Ochsner site will contribute to uncovering additional genes as well as examine health disparities and care access for ...